Amiodarone

"Amiodarone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.

Descriptor ID	D000638
MeSH Number(s)	D03.633.100.127.075
Concept/Terms	Amiodarone Amiodarone Amiodarona Amiodarona Amiodarone Hydrochloride Amiodarone Hydrochloride Hydrochloride, Amiodarone Amiohexal Amiohexal Aratac Aratac Tachydaron Tachydaron Corbionax Corbionax Cordarone Cordarone Amiodarex Trangorex Kordaron Cordarex L-3428 L-3428 L 3428 L3428 Ortacrone Ortacrone Rytmarone Rytmarone SKF 33134-A SKF 33134-A SKF 33134 A SKF 33134A Amiobeta Amiobeta Braxan Braxan

Below are MeSH descriptors whose meaning is more general than "Amiodarone".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, Fused-Ring [D03.633]
Heterocyclic Compounds, 2-Ring [D03.633.100]
Benzofurans [D03.633.100.127]
Amiodarone [D03.633.100.127.075]

Below are MeSH descriptors whose meaning is related to "Amiodarone".

Below are MeSH descriptors whose meaning is more specific than "Amiodarone".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Amiodarone" by people in this website by year, and whether "Amiodarone" was a major or minor topic of these publications.

Bar chart showing 65 publications over 20 distinct years, with a maximum of 7 publications in 2009

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1998	1	0	1
2002	2	0	2
2003	1	1	2
2004	1	0	1
2005	2	3	5
2006	1	0	1
2007	5	1	6
2008	3	2	5
2009	7	0	7
2010	3	3	6
2011	4	1	5
2012	2	0	2
2013	2	0	2
2014	2	1	3
2015	3	0	3
2016	3	0	3
2018	0	2	2
2019	2	0	2
2020	0	1	1
2022	6	0	6

Below are the most recent publications written about "Amiodarone" by people in Profiles.

Naccarelli GV, Kowey PR. Should we limit antiarrhythmic drug choice in patients with left ventricular hypertrophy? J Cardiovasc Electrophysiol. 2023 Feb; 34(2):453-454.

View in: PubMed
Handelsman Y, Bunch TJ, Rodbard HW, Steinberg BA, Thind M, Bigot G, Konigsberg L, Wieloch M, Kowey PR. Impact of dronedarone on patients with atrial fibrillation and diabetes: A sub-analysis of the ATHENA and EURIDIS/ADONIS studies. J Diabetes Complications. 2022 07; 36(7):108227.

View in: PubMed
Mar PL, Horbal P, Chung MK, Dukes JW, Ezekowitz M, Lakkireddy D, Lip GYH, Miletello M, Noseworthy PA, Reiffel JA, Tisdale JE, Olshansky B, Gopinathannair R. Drug Interactions Affecting Antiarrhythmic Drug Use. Circ Arrhythm Electrophysiol. 2022 05; 15(5):e007955.

View in: PubMed
Camm AJ, Blomstr?m-Lundqvist C, Boriani G, Goette A, Kowey PR, Merino JL, Piccini JP, Saksena S, Reiffel JA. AIM-AF: A Physician Survey in the United States and Europe. J Am Heart Assoc. 2022 03 15; 11(6):e023838.

View in: PubMed
Thind M, McKindley DS, Reiffel JA, Naccarelli GV, Stewart J, Kowey PR. Predictors of dronedarone plasma drug concentrations and effect on atrial fibrillation/atrial flutter recurrence: Analyses from the EURIDIS and ADONIS studies. Clin Cardiol. 2022 Jan; 45(1):119-128.

View in: PubMed
Thind M, Zareba W, Atar D, Crijns HJGM, Zhu J, Pak HN, Reiffel J, Ludwigs U, Wieloch M, Stewart J, Kowey P. Efficacy and safety of dronedarone versus placebo in patients with atrial fibrillation stratified according to renal function: Post hoc analyses of the EURIDIS-ADONIS trials. Clin Cardiol. 2022 Jan; 45(1):101-109.

View in: PubMed
Bosch NA, Rucci JM, Massaro JM, Winter MR, Quinn EK, Chon KH, McManus DD, Walkey AJ. Comparative Effectiveness of Heart Rate Control Medications for the Treatment of Sepsis-Associated Atrial Fibrillation. Chest. 2021 04; 159(4):1452-1459.

View in: PubMed
Pokorney SD, Holmes DN, Shrader P, Thomas L, Fonarow GC, Mahaffey KW, Gersh BJ, Kowey PR, Naccarelli GV, Freeman JV, Singer DE, Washam JB, Peterson ED, Piccini JP, Reiffel JA. Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation. Am Heart J. 2020 02; 220:145-154.

View in: PubMed
Rajapreyar I, Acharya D, Tallaj J, Hornbuckle L, Sharpton J, Joly J, Pamboukian S. Left Ventricular Assist Device Thrombosis-Amiodarone-Induced Hyperthyroidism: Causal Link? ASAIO J. 2019 02; 65(2):e18-e20.

View in: PubMed
Soar J, Donnino MW, Maconochie I, Aickin R, Atkins DL, Andersen LW, Berg KM, Bingham R, B?ttiger BW, Callaway CW, Couper K, Couto TB, de Caen AR, Deakin CD, Drennan IR, Guerguerian AM, Lavonas EJ, Meaney PA, Nadkarni VM, Neumar RW, Ng KC, Nicholson TC, Nuthall GA, Ohshimo S, O'Neil BJ, Ong GY, Paiva EF, Parr MJ, Reis AG, Reynolds JC, Ristagno G, Sandroni C, Schexnayder SM, Scholefield BR, Shimizu N, Tijssen JA, Van de Voorde P, Wang TL, Welsford M, Hazinski MF, Nolan JP, Morley PT. 2018 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations Summary. Circulation. 2018 12 04; 138(23):e714-e730.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement